ENVERIC BIOSCIENCES, INC. Restructuring and Related Cost, Cost Incurred to Date
ENVERIC BIOSCIENCES, INC. (ENVB) had Restructuring and Related Cost, Cost Incurred to Date of $113.53 thousand as of 2024-03-31, per its 10-Q filed 2024-05-15.
Financial Statements › Notes
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2025-03-28
- 2024-03-31: Restructuring and Related Cost, Cost Incurred to Date $113.53K.
- 2023-12-31: Restructuring and Related Cost, Cost Incurred to Date $301.64K.
- 2023-09-30: Restructuring and Related Cost, Cost Incurred to Date $607.60K.
- 2023-06-30: Restructuring and Related Cost, Cost Incurred to Date $726.72K.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2024-03-31 | $113.53K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $301.64K 10-K · filed 2025-03-28 |
| 2023-09-30 | $607.60K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $726.72K 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |